STOCK TITAN

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will speak at two upcoming investor conferences. The first is the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 10:20 AM ET, where he will participate in a Targeted Oncology panel. The second event is the Canaccord Genuity 41st Annual Growth Conference, scheduled for August 12, 2021, at 1:00 PM ET. Webcasts of the presentations will be available on the company's website, along with replays for three weeks.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:

  • The 2021 Wedbush PacGrow Healthcare Conference. Dr. Epstein will be featured in a Targeted Oncology panel on Wednesday, August 11, 2021 at 10:20 AM ET. The session will be available via live webcast to conference attendees.
  • The Canaccord Genuity 41st Annual Growth Conference. The presentation will take place on Thursday, August 12, 2021 at 1:00 PM ET.

A live webcast of the Canaccord Genuity presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com

Contacts
For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


FAQ

What is the schedule for Black Diamond Therapeutics' presentations in August 2021?

Black Diamond Therapeutics will present at the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 10:20 AM ET, and at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 1:00 PM ET.

Who will represent Black Diamond Therapeutics at the investor conferences?

David M. Epstein, Ph.D., the CEO of Black Diamond Therapeutics, will represent the company at both investor conferences.

Where can I watch the Black Diamond Therapeutics presentations?

The presentations can be watched via live webcast on the investor relations section of the Black Diamond Therapeutics website.

How long will the webcasts of Black Diamond Therapeutics' presentations be available?

The replays of the presentations will be available and archived on the Black Diamond Therapeutics website for three weeks.

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

BDTX Latest News

BDTX Stock Data

125.34M
55.24M
2.26%
98.75%
10.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE